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Abstract
The carboxyl terminus of HSP70-interacting protein (CHIP) is a ubiquitin ligase/co-chaperone
critical for the maintenance of cardiac function. Mice lacking CHIP (CHIP −/−) suffer decreased
survival, enhanced myocardial injury, and increased arrhythmias compared to wild type controls
following challenge with cardiac ischemia reperfusion injury. Recent evidence implicates a role
for CHIP in chaperone-assisted selective autophagy, a process that is associated with exercise-
induced cardioprotection. To determine whether CHIP is involved in cardiac autophagy, we
challenged CHIP −/− mice with voluntary exercise. CHIP −/− mice respond to exercise with an
enhanced autophagic response that is associated with an exaggerated cardiac hypertrophy
phenotype. No impairment of function was identified in the CHIP −/− mice by serial
echocardiography over the five weeks of running, indicating that the cardiac hypertrophy was
physiologic not pathologic in nature. It was further determined that CHIP plays a role in inhibiting
Akt signaling and autophagy determined by autophagic flux in cardiomyocytes and in the intact
heart. Taken together, cardiac CHIP appears to play a role in regulating autophagy during the
development of cardiac hypertrophy, possibly by its role in supporting Akt signaling, induced by
voluntary running in vivo.
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Introduction
The carboxyl terminus of Hsp70-interacting protein (CHIP) is a ubiquitin ligase/co-
chaperone that is critical for the maintenance of cardiac function, largely through its
influence on protein quality control pathways. CHIP regulates protein quality control in 2
distinct ways. First, CHIP binds to protein substrates to mediate their refolding though its
co-chaperone activity and interaction with the heat shock protein Hsp70 1, 2. Second, CHIP
recognizes, ubiquitinates, and degrades unfolded chaperone substrates as a U-box-dependent
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ubiquitin ligase and co-chaperone/chaperone 3-6. The importance of CHIP's function as a
regulator of cardiac protein quality control is illustrated by the fact that CHIP −/− mice are
unable to withstand the cardiac challenge brought about by ischemia/reperfusion (I/R)
injury, suffering decreased survival and an increase in arrhythmias and myocardial injury 7.
Recently, CHIP's involvement in the maintenance of protein quality control has been
extended to include the process of autophagy 8. In both Drosophila and mouse striated
muscle, CHIP colocalizes with the cochaperone molecule BAG-3 (Starvin in Drosophila
cells) in a multiprotein complex situated at the Z-disc and facilitates the ubiquitin-dependent
autophagic degradation of the sarcomeric protein filamin 8. This process of autophagy has
been termed chaperone-assisted selective autophagy (CASA) to distinguish it from the
related process of chaperone-mediated autophagy, which involves the ubiquitin-independent
translocation of a target substrate across the lysosomal membrane 9.
In the heart, autophagy is an integral component of the molecular mechanisms involved in
regulating cardiac protein quality control. Autophagy of cardiac proteins is associated with
exercise-induced cardioprotection 1011 and with the remodeling response to cardiac
hypertrophy and other stressors (see recent reviews 12, 13). These stressors, such as I/R
injury, can regulate the amount of autophagy within the cell, which in turn can determine a
cell's susceptibility to damage. For example, autophagic flux through the macroautophagy
pathway, a measure of autophagosome clearance, is markedly impaired with reperfusion
(reoxygenation) after an ischemic (hypoxic) insult14. Autophagy impairment may contribute
to I/R-induced cardiomyocyte cell death by failing to clear damaged mitochondria and
misfolded proteins formed in response to enhanced oxidative stress15. When pre-
conditioning against I/R, the challenge of a brief ischemia to induce subsequent protection
against I/R injury, autophagy has been found to be essential for cardioprotection and related
to its regulation of mitochondrial permeability pore16, 17. Enhancing autophagy protects
against I/R injury18 through its enhanced turnover of damaged mitochondria by ubiquitin
ligases such as Parkin and the autophagic adapter protein p62, which directly translocates to
mitochondria to mediate this clearance 19. Others have hypothesized that misfolded proteins
accumulating in I/R injury are cleared by autophagy and prevent an accelerated heart failure
by preventing protein aggregate proteotoxicity (cell death)12, 20, 21. The enhanced removal
of ROS-producing mitochondria by autophagy can also decrease the oxidative stress
experienced by a cell; this explains how caloric restriction, which potently induces
autophagy, is associated with less damage when challenged with oxidative stress 22. These
multiple lines of evidence link the ubiquitin proteasome system with the autophagic
clearance of mitochondria and misfolded proteins, resulting in enhanced cellular
performance in the face of oxidative stress.
It is already well-documented that the ubiquitin ligase CHIP plays a critical role in
maintaining cardiac structure and function during times of stress, prompted us to examine
whether CHIP is involved in autophagic protein degradation in the heart. To examine this,
we used voluntary unloaded wheel running, an established model of physiologic cardiac
hypertrophy 23-25, to determine whether cardiac autophagy could be induced as it is in other
muscles in response to exercise 26-28. We found that hearts from CHIP −/− mice respond to
voluntary exercise with an enhanced autophagic response that is associated with an
exaggerated hypertrophic phenotype. We further determined that CHIP plays a role in
regulating Akt signaling in cardiomyocytes. These findings implicate for the first time a role
for cardiac CHIP in regulating the autophagic response and the involvement of Akt in
physiologic cardiac hypertrophy.
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CHIP −/− mice were generated and maintained on a mixed genetic background of C57/BL6
and 129SvEv 29. Mice in the present study were 24 weeks of age at the beginning of the
study. Mice were euthanized after 5 weeks of wheel running exercise (or sham exercise,
described below) and hearts were processed in one of two ways: 1) fixed in 4%
paraformaldehyde, processed for paraffin embedding, and subsequently sectioned and
stained with standard hematoxylin and eosin (H&E) and Masson's Trichrome; or 2) fixed in
a freshly prepared solution of 2% paraformaldehyde/2.5% glutaraldehyde in 0.15 M sodium
phosphate buffer, pH 7.4, processed for electron microscopy and imaged using a LEO
EM910 transmission electron microscopy at 80 kV (LEO Electron Microscopy Ltd.. Images
of transmission electron micrographs were obtained using a Gatan Bioscan Digital Camera
(Gatan, Inc.). H&E and Masson's Trichrome stained slides were scanned using an Aperio
Scancope and exported using Aperio Imagescope software (Version 10.0.36.1805, Aperio
Technologies, Inc.). All animal husbandry and experiments were approved by the
institutional care and use committee (IACUC) for animal research at the University of North
Carolina at Chapel Hill.
Measuring cross sectional area of cardiomyocytes
Paraffin embedded heart sections were stained with a TRITC-labeled lectin as previously
described 30. Cardiomyocyte cross sectional area was measured using Image J software. A
minimum of 20 random fields at 200× magnification in the left ventricle were imaged from
at least 3 different hearts. A minimum of 100 cardiomyocytes per heart were measured for
calculating the average of cross sectional area.
Unloaded voluntary wheel exercise–induced cardiac hypertrophy
A voluntary, unloaded wheel exercise challenge was used to induce physiologic hypertrophy
in female mice as previously described 31. Briefly, mice were assigned to either unloaded
(no-resistance) wheel running (N=16) or sedentary control groups (N=16). Wild-type
littermates were similarly assigned to either unloaded wheel running or sedentary control
groups (N=14 per group). Exercise wheel use was monitored using a Mity 8 Cyclocomputer
(model CC-MT400), recording distance, average speed, maximum speed, and running time.
Running statistics were recorded daily. Only mice with completed data sets were included in
the running statistics shown in Supplemental Figure 1A. Hearts were morphometrically
analyzed by echocardiography at baseline before voluntarily exercise was initiated and after
5 weeks of exercise, as previously described 32. Mice were sacrificed via isoflurane
inhalation overdose and subsequent cervical dislocation before organs were harvested for
further analysis.
Echocardiography
Cardiac trans-thoracic echocardiography was performed on conscious mice using a
VisualSonics Vevo 770 ultrasound biomicroscopy system (VisualSonics, Inc.) using the
707B scan head (30 MHz; blinded to mouse genotype and treatment) as previously
described 33, 34. Two-dimensional guided M-mode was performed in the parasternal long-
axis and short-axis at the level of the papillary muscle. Epicardial to endocardial leading
edges were used to measure anterior and posterior wall thicknesses and left ventricular
internal diameters. Left ventricular systolic function was assessed by ejection fraction (LV
EF%=[ (LV Vol;d-LV Vol;s/LV Vol;d)*100] and fractional shortening (%FS=[(LVEDD-
LVESD)/LVEDD] × 100). M-mode measurements represent 3 average consecutive cardiac
cycles from each mouse.
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The cardiac-derived HL-1 cell line was used to create stably transduced cell lines with CHIP
knockdown using lentivirus shRNA. Briefly, HL-1 cells 35 were treated with lentivirus
expressing CHIP shRNA (lentiviral vectors were obtained from Open Biosystems, CHIP
shRNA, Cat.#s TRCN0000008528, TRCN0000008527 and TRCN0000008530; empty
vector pLKO1, Cat.#RHS4080) to knock-down CHIP. After 24 hours, cells were selected
with puromycin (3ug/ml) for 48hr, a time point where all control cells had died. The
surviving cells were then expanded and stored in liquid nitrogen with freezing media. Cells
were cultured in serum free DMEM for 16 hours prior to experiments, then treated with 10
ng/ml IGF-1 (Cat.#I1146, Sigma-Aldrich, St. Louis, MO) for 30 minutes or 4 hours,
harvested and prepared for Western blot analysis.
Immunoblotting and real-time PCR analysis
Heart tissue was snap frozen in liquid nitrogen, homogenized in RIPA buffer and
centrifuged at 14,000 × g for 15 minutes at 4C to remove cell debris. Protein concentration
of the supernatant was determined using a BCA assay (Thermo Fisher Scientific, Inc.).
Thirty to fifty μg of protein was loaded onto PAGE, transferred to PVDF membranes and
immunoblotted. Membranes were blocked in 3% skim milk in 1× PBS, incubated with
primary antibody (1:2000 dilution in blocking buffer, unless otherwise indicated) overnight
at 4C and incubated with HRP-conjugated secondary antibody (1:10,000 dilution in
blocking buffer) for 1 hour at room temperature before being processed using the ECL
detection system (Amersham ECL Plus™ Western Blotting Detection Reagents). Primary
antibodies for AKT (Cat.#9272), pAKT(S473) (Cat.#9271), pGSK3α(S21) (Cat.#9316), and
anti-pGSK3β(S9) (Cat.#9336), and LC3B (Cat.#3868) were purchased from Cell Signaling
Technology, Inc. Antibodies recognizing LC3B (Cat.#L7543, 1:500) in tissue, GAPDH
(Cat.#G8795, 1:4000), and β-tubulin (Cat.#T8328, 1:4000) were purchased from Sigma-
Aldrich. Antibody recognizing total GSK3 (Cat.#44-610) was purchased from Invitrogen,
Inc. Antibodies specific for CHIP (Millipore, Cat.#AB10000) were used in Western blot
analysis. For real-time PCR analysis, total RNA from hearts was extracted using Trizol
(Invitrogen Corporation, Cat.#15596-026) solution. cDNA was synthesized using GoScript
reverse transcription kit (Promega Corporation, Cat.#A5000) and primer pairs for real-time
PCR were designed using Roche Applied Science Universal Probe Library Web (https://
www.roche-applied-science.com/sis/rtpcr/upl/index.jsp?id=uplct_000000). The specific
primers and probes from the mouse Universal ProbeLibrary Set, (Roche) are detailed in
Supplemental Table 1. β-MHC mRNA expression was determined using the
Mm00600555_m1 TaqMan Probe (Applied Biosystems). All qRT-PCR results were
normalized to 18S (TaqMan Probe, Hs99999901_s1) mRNA expression.
Determination of autophagic flux both in vitro and in vivo
Autophagic flux was determined in vivo based on the titration of bafilomycin A1 doses over
time to optimize animal survival without eliciting any other major dysfunction, while
effectively inhibiting autophagy as previously described 36, 37. Briefly, stock bafilomycin
A1 (BFA, cat# sc-201550A, Santa Cruz Biotechnology, Santa Cruz, CA)(3 mM stock in
DMSO) was diluted in PBS (40% DMSO final). Mice were then treated with this dilution to
a final of 3 μmol/kg by intraperitoneal injection (in ∼200 μl total). One hour later, a second
equivalent injection was given. Mice were euthanized and tissues collected for further
analysis by Western immunoblot for LC3B isoforms one hour after the second injection. To
determine autophagic flux in vitro, cells were treated with 100 nM bafilomycin A1 2 hours
prior to harvest.
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A Student's t-test (GraphPad Prism 5) was performed on all compared values to obtain
statistical significance or ANOVA with Holm-Sidak pairwise post hoc analysis (Sigma Stat
3.5). Significance was defined as a p value less than 0.05.
Results
CHIP−/− mice display increased markers of cardiac autophagy following voluntary
exercise
CHIP has a number of cellular functions, including supporting protein refolding through its
interactions with heat shock proteins (Hsp70/BAG2), and also degrading proteins by its
ubiquitin ligase activity 38, 39. CHIP's role in protein quality control has recently been shown
to be even more diverse by the discovery that CHIP can be involved in the process of
autophagy 8, 40. Specifically, these studies have identified that the HSPB8/BAG3/HSC70/
CHIP multi-heteromeric complex selectively activates autophagic removal of misfolded
proteins in Drosophila muscle and mouse systems 8, 40. Since autophagy is now appreciated
as a factor involved in the development of a variety of cardiac stressors, including
hypertrophy 12, 41, we decided to investigate the autophagic activity in hearts from CHIP −/−
mice following 5 weeks of voluntary running.
Cardiac autophagy was evaluated by measuring the expression of autophagic-associated
genes, transmission electron microscopy, and by autophagic flux in sham and running CHIP
−/− and wildtype control mice. RT-PCR analysis of CHIP −/− hearts identified increases in
autophagy-related genes GabarapL1, Atg7, Atg5, Vps34, and Bnip3 after 5 weeks of running
(Figure 1A, right), suggesting that increased autophagic activity may be present in CHIP −/−
hearts after voluntary running. Transmission electron microscopy analysis of tissue sections
from hearts of CHIP −/− running mice revealed increases the presence of membrane bound
autophagosomes/autolysosomes containing mitochondrial cellular material indicative of
autophagy (Figure 1B). These structural changes were not seen in sections taken from hearts
of CHIP −/− mice in the sham CHIP −/− mice or in hearts isolated from sham or running
wildtype mice. After one week of running, autophagic flux in the heart measured by LC3BII
expression after bafilomycin treatment indicated an enhanced autophagic response in CHIP
−/− mice compared to wild type controls (Figure 2A vs. steady state LC3B levels
Supplemental Figure 1B). Taken together, the real time analysis of genes involved in
autophagy, the TEM identification of mitochondria in vesicles, and an increase in
autophagic flux demonstrate that voluntary exercise stimulates autophagic activity in the
hearts of CHIP −/− mice, but not wild-type mice, suggesting that CHIP is involved in
attenuating cardiac autophagy due to increased cardiac demand.
Chaperone-mediated autophagy occurs during conditions of cellular stress and is responsible
for degrading ∼30% of cytosolic proteins 42, 43. Substrates for this degradative pathway
contain a pentapeptide motif (KFERQ) that is selectively recognized by the heat shock
cognate protein of 70 kDa (Hsc70) 44. When substrates interact with the chaperone, it targets
the complex to the lysosomal membrane where it binds the protein LAMP2A 45. Since
LAMP2A (lysosomal membrane bound lysosomal-associated membrane protein 2A) is
increased during chaperone-mediated autophagy 46, 47, we used real time PCR to investigate
the expression of LAMP2A and the lysosomal Cathepsin L in the hearts from CHIP −/− mice
after 5 weeks of voluntary running (Figure 2B). We found that hearts from CHIP −/− mice
that had undergone 5 weeks of voluntary exercise, but not wild-type mice from the running
group, had an ∼2.4 fold increase in LAMP2A and an ∼3.2 fold increase in Cathepsin L
compared to mice of either genotype from the control group. The increase in both LAMP2A
and Cathepsin L during exercise in the CHIP-deficient hearts is consistent with the data
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collected from RT-PCR, TEM, and autophagic flux studies indicating the presence of
enhanced autophagic activity, a process that is not active in the hearts from wild-type mice
voluntarily running.
Cardiac CHIP modulates cardiomyocyte size in voluntary exercise
Voluntary running in wild-type mice induced cardiac hypertrophy as determined by a 28.8%
increase in heart weight/body weight (HW/BW; 5.33 vs. 4.14 mg/g in the sham control
group), a 23.1% increase in cardiomyocyte cross sectional area (2.05 vs. 1.66 microns2 in
the control group), and ∼12% increase in the anterior and posterior wall thicknesses in
diastole (1.13 vs. 1.0 mm in the sham control group; Figure 3A-3F, Table 1). In contrast,
CHIP −/− mice in the run group exhibited an exaggerated hypertrophy compared to their
baseline, resulting in a 49.5% greater HW/BW than hearts from CHIP −/− sham (7.98 vs.
5.35 mg/g in the sham control group), a 69.9% increase in cardiomyocyte cross sectional
areas (2.95 vs. 1.74 microns2), and ∼ 40-46% greater thicknesses of the anterior (∼46.3%,
1.47 vs. 1.0 mm) and posterior (∼40%, 1.35 vs. 0.97 mm) ventricular wall thicknesses in
diastole as determined by echocardiography (Table 1). CHIP −/− mice have previously been
shown to have a progressive weight loss over time due to decreases in muscle and fat mass
(atrophy) 29. This may account for the disproportionate increase in HW/BW vs. the cross-
sectional areas of the CHIP −/− and type mice, which has previously been reported 29. The
running performance of both CHIP −/− and wild-type mice improved during the course of
voluntary running (Supplemental Figure 1A). No differences in the soleus skeletal muscle
weights were identified in CHIP −/− mice after running, indicating the increases in cardiac
hypertrophy in the CHIP −/− mice were not a uniform response of CHIP −/− striated muscle
(Supplemental Figure 2).
The exaggerated changes observed in hearts of CHIP −/− in response to running suggested
CHIP's involvement in the regulation of cardiac hypertrophy. Activation of the IGF-1
signaling pathway enhances the development of muscle hypertrophy in response to
exercise 48, 49. IGF-1 activates PI-3-kinase, which phosphorylates pyruvate dehydrogenase
kinase (PDK), which then phosphorylates Akt, activating its ability to phosphorylate
downstream GSK3β and p70 S6 kinase 50. Voluntary running in mice induces the IGF-1/
PI3K/Akt signal transduction pathway, ultimately resulting in increased GSK3β signaling
and leading to physiologic cardiac hypertrophy 31, 51. Recent studies have implicated CHIP
in the regulation of Akt in neurons. Specifically, during stress, CHIP ubiquitinates and
degrades Akt in an HSP90 complex-dependent manner 5, 6, 52. Conversely, Akt activity
tightly regulates CHIP expression, suggesting a feedback response mechanism 5, 6, 52. Since
CHIP negatively regulates Akt signaling critical to the development of physiologic cardiac
hypertrophy, challenging CHIP −/− mice to voluntary running would be expected to have an
enhanced Akt response and an enhanced cardiac hypertrophy, which is consistent with our
phenotypic findings above.
To investigate whether CHIP plays a role in regulating Akt signaling in cardiomyocytes as it
does in neurons under stress, we performed Western immunoblot analysis on HL-1 cardiac-
derived cells stimulated with IGF-153-55. When stimulated with IGF-1, HL-1 cell lines with
stable shRNA CHIP knockdown exhibited an exaggerated p-Akt (ser473) compared to
shRNA scramble controls (Figure 4A/4B). Since recent studies have linked the Akt
signaling pathway to the regulation of autophagy 56, 57, we next determined how CHIP's
regulation of Akt might be linked to the autophagic flux identified in the shRNA CHIP (−/−)
cells. Interestingly, we identified that knocking down CHIP expression resulted in an
enhanced LC3B II expression compared to controls in the presence of bafilomycin both at
baseline and in the presence of IGF-1 (Figure 4C). Taken together, these findings suggested
that cardiomyocytes lacking CHIP experienced an enhanced Akt signaling that was
associated with an increase in autophagic flux.
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The enhanced hypertrophy and performance seen in CHIP−/− mice is not associated with
enhanced fibrosis or decreased cardiac function
Histological analysis of hearts from control and running CHIP −/− mice was performed to
determine any morphological and fibrotic changes, indicative of pathological hypertrophy.
Tissue sections taken from hearts of CHIP −/− mice in the running group exhibited no
cellular infiltrates or fibrosis, as determined by staining sections with either Mason's
Trichrome or H&E, respectively (Figure 5A, Supplemental Figure 3). A similar finding was
seen in tissue sections taken from wild-type mice in the running group (Figure 5A,
Supplemental Figure 3). RT-PCR analysis of β-myosin heavy chain (β-MHC), brain
natriuretic peptide (BNP), and atrial natriuretic factor (ANF) mRNA expression (genes
associated with the “fetal program” seen in pathological cardiac hypertrophy) revealed no
significant increases in gene expression in the hearts of CHIP −/− compared to wild-type
mice in either the control or running groups, although a near two-fold change in ANF was
seen in CHIP −/− hearts at baseline and after running (Figure 5B). Previous studies have
reported the CHIP −/− heart function is stable for up to a year of age 7; however, CHIP −/−
mice demonstrate an increased cellular senescence. So it is not clear if this increased ANF
expression reflects early “fetal gene” expression or is related to other non-related issues.
Despite the fact that CHIP −/− mice exhibited an exaggerated cardiac hypertrophy compared
to wild-type mice after running, no change in cardiac systolic function between the two
groups was observed, as indicated by echocardiographic determination of fractional
shortening % and ejection fraction % (Figure 5C). Differences in cardiac ATP levels were
not seen in CHIP −/− mice compared to controls either (Supplemental Figure 2). These
results indicate that the increased cardiac hypertrophy seen in CHIP −/− mice following 5
weeks of voluntary running is not associated with fibrosis, histological evidence of
pathology, or defects in cardiac function at the time point investigated.
Discussion
In this report, we have used a mouse model of unloaded, voluntary running to identify for
the first time that the ubiquitin ligase/co-chaperone CHIP (carboxyl terminus of Hsp70-
interacting protein) regulates physiologic cardiac hypertrophy and autophagy. This is an
exciting finding given the previous reports identifying cardiac CHIP as a key regulator of
cell death in the context of ischemia and hyperglycemia-induced cardiomyocyte
injury7, 58, 59.
In the present study we identified that CHIP −/− hearts had enhanced autophagy determined
by TEM, real time analysis of proteins involved in autophagy, including Atg7, Atg5, and
Vps34. Our understanding of the role autophagy plays in the heart has increased
tremendously in the past couple of years. There are numerous molecular components
involved with autophagy, including Atg1 and Atg4-12 60. In addition, numerous signaling
pathways regulate autophagy, including Akt regulated mTOR, AMPK and the p53 signaling
cascade 60. Autophagy of damaged cellular components, including the degradation of
damaged cellular components as a means of protein and organelle protein quality control,
occurs under physiological conditions in the heart, as illustrated in mice lacking either Atg5
or Atg7 (inhibiting autophagy), which suffer from cardiac failure without any inducing
stimuli 61, 62. However, autophagy is also critical for afterload-induced changes in the heart,
as well as during myocardial infarction and ischemia/reperfusion insults 60.
Despite what is known about the role of autophagy in basal cardiac regulation and response
to cardiac disease states, a role for autophagy in physiologic cardiac hypertrophy, has not
been previously published, to our knowledge. However, in skeletal muscle, strenuous
exercise inducing muscle damage has been reported to induce an autophagic response 63.
Specifically, in mice challenged with 9 hours of running, necrotic fibers first appear within
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24 hours after exertion. An enhanced autophagic response in these mice is most prominent
between 2 and 7 days after exertion, illustrated by vacuoles with double or single limiting
membranes containing mitochondria at various stages of degradation 63. The enhanced
autophagy in response to running is thought to be related to the breakdown of cellular
constituents that could be recycled to provide resources for regenerating muscle fibers 63. In
addition to exercise, both muscle damage and the accumulation of misfolded proteins are
known to induce autophagy in cardiomyocytes 64, 65. In mouse models of human
cardiomyopathies, genetic mutations of the small heat shock protein αB-Crystallin
(CryABR120G) result in the accumulation of misfolded CryABR120G protein in the form of
preamyloid oligomers and aggresomes64. These oligomers and aggresome then induce a
severe cardiomyopathy resulting from an inhibition of autophagy64. Further inhibiting
autophagy by silencing Atg7, a required intermediate for autophagy, results in an increase in
CryABR120G aggregate content and cytotoxicity. Conversely, enhanced Atg7 expression
rescues the CryABR120G autophagic deficiency and attenuates misfolded protein
accumulation and aggregates in cardiomyocytes, illustrating the critical role of autophagy in
clearing misfolded CryABR120G proteins 64. Extending these elegant studies of
CryABR120G, subsequent studies have demonstrated that expressing an 83 residue,
misfolded polyglutamine (PQ83) peptide in the heart itself can induce heat failure, whereas
a non-amyloid-forming polyglutamine peptide of 19 residues (PQ19) does not 66. Taken
together, these studies illustrate the role for an autophagic response in exercise and
demonstrate an advantage to enhancing autophagy to clear misfolded proteins, resulting in
preserved cardiomyocyte viability and function. Similarly, the enhanced performance seen
in the CHIP −/− mice in the current study may be due to enhanced autophagy after running
that more efficiently clears misfolded proteins and/or mitochondria that accumulate during
voluntary running.
We have previously demonstrated that the CHIP −/− mouse used in the current study has
altered protein quality control, leading to an increase in misfolded proteins 29. The increase
in autophagy in the hearts from CHIP −/− mice reported in this study may reflect a
compensatory mechanism used by cardiomyocytes to decrease the burden of damaged or
misfolded proteins that arise as a result of the increase in cardiac work load. Alternatively,
the increased autophagic activity may indicate that, under normal physiological conditions,
CHIP inhibits autophagy. Since Hsc70 is critical for both CHIP's chaperone functions and
the process of chaperone mediated autophagy, it is possible that when CHIP is present it
targets Hsc70 for ubiquitination and proteasomal degradation thereby limiting its availability
for autophagic activity. Regardless of the mechanism, these findings suggest a role for
cardiac CHIP in autophagy in general, and in chaperone-mediated autophagy more
specifically, during exercise-mediated cardiac stress.
Recent studies have implicated CHIP in the regulation of Akt signaling in neuronal cells,
consistent with the findings in the current paper5, 6, 52. Akt is required for the development
of the physiologic cardiac hypertrophy that occurs in response to exercise and IGF-1
stimulation 67, 68. At the same time, signaling through the Akt pathway antagonizes the
development of pathologic hypertrophy 67, 69, 70. IGF-1, increased through different forms
of exercise, mediates the physiologic growth of cardiomyocytes by stimulating an increase
in GSK3β phosphorylation, thereby inhibiting its activity and inducing increases in protein
synthesis via mTOR 71. Our observations of enhanced Akt/GSK3β signaling in CHIP−/−
cardiomyocytes following voluntary exercise explains, in part, the enhanced physiologic
hypertrophy identified in these mice. It also indicates a role for CHIP in regulating Akt
signaling in exercise-induced cardiac hypertrophy.
Previous studies have begun to form a link between CHIP and the regulation of Akt in
neurons, but the exact nature of this relationship in the context of the current study is not
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clear 5, 6, 52. Similar to the accumulation of proteotoxic aggregates that form in human heart
failure 72 and in genetic cardiac diseases described above 73-75, Alzheimer's disease results
in the accumulation of the microtubule-associated protein tau that forms fibrillar aggregates
and become toxic to the neurons in which they form 52. During stress, Akt is ubiquitinated
and degraded by CHIP; Akt also prevents CHIP-induced tau ubiquitination and
degradation52. This feedback mechanism(s) between kinase and ubiquitin ligase illustrates
the novel interaction between tau kinases (Akt) and protein quality control (CHIP) that lead
to the common pathways of proteotoxity and dysfunction seen in Alzheimer's disease 52. In
the CHIP −/− mice challenged with running described in the current manuscript, the link
between Akt-induced cardiomyocyte growth and protein quality control may be similarly
linked. CHIP may attenuate both Akt signaling and autophagy in the heart during exercise,
resulting in both the beneficial growth (Akt activation) and enhanced autophagy (protein
quality control including clearance of misfolded proteins). The details of how CHIP
regulates Akt remains to be delineated in the heart, but possibly involves the proteasomal
degradation of Akt during stress, autophagy and other signaling pathways involved in
physiologic and pathologic hypertrophy.
Recent studies have linked the regulation of Akt signaling to autophagy. Stimulation of
IGF-1 activates downstream PI3K, Akt, and the transcription factors FOXO3 & FOXO4.
Cell lines ectopically expressing conditionally active variants of PI3K, Akt, FOXO3, and
FOXO4 have recently been identified to up-regulate the expression of glutamine
synthetase56. The activation of FOXO-induced glutamine synthetase expression increases
the level of autophagy; the mechanism is believed to involve the glutamine synthetase
regulation of mTOR, which is evolutionarily conserved to negatively regulate autophagy.
The enhanced FOXO3 activation in these studies resulted in an increased level of autophagy
measured by LC3 lipidation, p62 degradation, and the identification of autophagosomal
markers 56. While the present studies have not definitively proven that the enhanced Akt
signaling seen in response to running and IGF-1 is the cause of enhanced autophagy through
its activation of FOXO, it is one possible mechanism that would explain the unexpected
findings in the CHIP −/− hearts reported here.
While CHIP −/− hearts challenged with voluntary running exhibited increased autophagy by
molecular markers in the current study, transmission electron microscopy revealed clear
indications that the autophagy occurred predominantly in the areas where mitochondria were
found, with primarily mitochondria substrates identified within these enveloped vacuoles
(Figure 1). Mitochondrial autophagy (mitophagy) was first described the heart in 1980
following hypoxia in perfused rabbit hearts-it's presence was attributed to repair
mechanisms in damaged cells 76. Since this time, mitophagy has been shown to have a role
in mitochondrial protein quality control 77-81 and disease 82. The role of mitophagy in
protein quality control appears to play a critical role in maintaining mitochondrial integrity
critical to cellular homeostasis. When energy demand is low, having too many mitochondria
can be detrimental by generating more reactive oxygen species and if uncoupled, can
consume excess ATP 83. Eliminating mitochondria, particularly those that are damaged or
unstable and prone to inducing apoptosis, can reduce the damage to both neighboring
mitochondria and the entire cell 84. Autophagic removal of mitochondria follows both
induction and inhibition of apoptosis 85, 86 suggesting a role for cell survival following
mitochondrial injury. The process of mitochondrial biogenesis, whereby growth and division
of preexisting mitochondria occurs, requires the coordination of multiple processes,
including synthesis of the inner and outer mitochondrial membranes, mitochondrial proteins;
synthesis and import of proteins encoded by the nuclear genome; replication of
mitochondrial DNA, and mitochondrial fission and fusion 12, 87. This subsequent critical
mitochondrial turnover then involves mitophagy followed by biogenesis 87.
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Basal levels of autophagy are required for cardiomyocytes to function and survive.
Autophagic recycling of damaged cellular proteins and organelles allows them to be
efficiently reused. When autophagic pathways are disrupted in the adult heart by inactivating
Atg5 or Atg7 genes, cardiac hypertrophy rapidly develops, along with left ventricular
dilation and diminished cardiac output 88, 89. Danon disease, also known as glycogen storage
disease type IIB, is marked by severe and progressive myopathy resulting from defective
autophagy, specifically a defect in the fusion of lysosomes with autophagosomes 90, 91.
Suppression of autophagy during fasting reduces intracellular ATP and results in diminished
cardiac function 92. Multiple recent studies illustrate that inducing autophagy can either
inhibit the progression of cardiac disease or contribute to the pathophysiology to accelerate
disease progression 93-95. Enhancing autophagy is protective during ischemia 96; and
conversely activating autophagy in pressure overload-induced cardiac hypertrophy 97 or
after ischemia reperfusion injury 96 is maladaptive. Autophagic flux is enhanced by the
amount of pressure overload in vivo 97, 98. Increasing autophagy by overexpression of
cardiomyocyte Beclin 1, pressure overload induced cardiac hypertrophy results in a rapid
transition to heart failure 99, whereas decreasing autophagy in Beclin 1 haplosufficient mice
attenuated the remodeling in pressure overload induced remodeling 97. In the context of
proteotoxic cardiomyopathy due to mutations in cardiac αB-crystallin (CryABR120G),
resulting in an increase is misfolded CryABR120G protein, enhanced autophagy helps
remove the accumulating toxic, misfolded, oxidized mutant proteins 20, giving support to the
concept that regulation of autophagy can be therapeutic, depending on the context of the
underlying cause of disease60. Recent studies have also suggested an interplay between
autophagy, glucose metabolism and cardiac hypertrophy; autophagy may also play a role in
supplying amino acids, nucleotides, sugars, and lipids to the energy pathways critical in the
heart (see recent reviews 95, 100).
While the enhanced Akt signaling seen in response to the challenge of physiological
hypertrophy induced by voluntary running appears beneficial in the current study, CHIP −/−
mice are more susceptible to injurious challenges. For example, in response to ischemia
reperfusion injury, CHIP −/− mice exhibit decreased survival and increased incidence of
arrhythmias during reperfusion 7. In addition, the size of the infarct area in the hearts of
CHIP −/− mice is >50% larger than sibling wild-type controls, an observation that correlates
with an increase in apoptosis of endothelial cells in intramural vessels 7. This increase in
endothelial cell apoptosis in the hearts of CHIP −/− mice is due in part to CHIP's role as an
endogenous p53 antagonist, suppressing p53 activity by ubiquitinating it and targeting it for
degradation by the proteasome 58. In experimental myocardial infarction induced in vivo,
CHIP overexpression prevents p53 accumulation, which in turn, prevents apoptosis,
indicating one of the mechanisms by which CHIP is cardioprotective 58. In hyperglycemia-
induced cardiomyocyte damage, CHIP regulates the steady state protein levels of the
transcription factor GATA4, likely by ubiquitin-dependent degradation 59. These studies
demonstrate CHIP's cardioprotective function of regulating key proteins involved in the
development of cardiac ischemia and pathologic cardiac hypertrophy, including the
transcription factors p53 and GATA4, respectfully. However, in other contexts, CHIP may
actually attenuate the beneficial signaling processes mediated by another key signaling
pathway, the Akt/GSK3β pathway, which is pivotal in the heart's response to physiologic
stress and exercise.
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Non-standard abbreviations and Acronyms
Atg autophagy
BAG2 Bcl2-associated athanogene 2
Bnip Bcl2 and adenovirus E1B 19 kDa-interacting protein 3
CHIP carboxyl terminus of HSP70-interacting protein
GSK3beta glycogen synthase kinase 3 beta
HSC70 heat shock cognate 70 kD protein
HSP70 heat shock protein 70
HSPB8 heat shock protein beta 8
LAMP2A lysosomal-associated membrane protein 2A
UPS ubiquitin proteasome system
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Figure 1. Enhanced autophagic process after voluntary exercise in CHIP−/− mouse
A. Quantitative real-time PCR analysis for indicated genes involved in autophagic process.
*p<0.05; **p<0.01 versus CON group. B. Representative TEM from CHIP +/+ and C. CHIP
−/− heart in RUN groups. M, mitochondria; white arrow head, autophagosomes containing
mitochondria. Data represent means ± SEM. Scale bar in each panel indicates 0.5 μm.
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Figure 2. CHIP−/− hearts have enhanced autophagic flux and lysosomal gene expression after
voluntary exercise
A. CHIP −/− hearts have an enhanced LC3B II expression after 1 week of voluntary running
compared to wild type controls (N=3/group). B. Quantitative real time PCR analysis for
Lamp2a and Cathepsin L genes. Relative mRNA expression of indicated genes in RUN
group (R) is normalized to CON group (C) of each genotype. 3-4 animals per each group
were used for RT-PCR analysis. Data represent means ± SEM. *p<0.05 versus genotype
matched sham group.
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Figure 3. Exaggerated cardiac hypertrophy in CHIP−/− mouse after voluntary exercise
A. Representative H&E stained heart section showing thicker left ventricle in CHIP−/−
mouse from running (RUN) groups. B. Heart weight (HW) to body weight (BW) ratio in
CHIP+/+ and CHP−/− mouse from CON (C) and RUN (R) groups. #, P<0.05 verses each
CON group; **, P<0.01 C. Quantification of cross sectional area (CSA) measured in lectin-
stained heart section from each group. Hearts from 3 to 6 mice were used and more than 200
cardiomyocytes per heart were counted. *p<0.05. D. Representative lectin stained heart
section from CHIP+/+ and CHIP−/− mouse in CON and RUN group. E & F. Anterior wall
(E, IVS;d) and Posterior wall (F, LVPW;d) thickness obtained from echocardiography. Data
represent means ± SEM. †p<0.001 verses each CON group; ***p<0.001 verses each CON
group; % p<0.001 vs. CHIP −/− Running; * vs. p<0.001 vs. CHIP +/+ Running.
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Figure 4. Knockdown CHIP augments IGF induced Akt signaling and enhanced autophagy in
HL-1 cardiac-derived cells
A. HL-1 cells with stable CHIP knockdown HL-1 cells (sh-CHIP), or control (Ctrl-sh) were
treated with 10 ng/ml IGF-1 for 30 minutes. Western analysis of CHIP, phospho-Akt and
total Akt were then performed and B. quantitatively and statistically analyzed (mean+_ S.D,
n=3 in each group) C. Stable CHIP knockdown HL-1 cells (shRNA CHIP=sh-CHIP) and
control HL-1 cells (shRNA CHIP=Ctrl-sh) were treated with 10 ng/ml IGF-1 for 4 hours
levels of autophagy were determined by Western blot of LC3B isoforms (blots represent the
results of 2 independent experiments). Data represent means ± SEM.
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Figure 5. CHIP−/− hearts do not show characteristics of pathological cardiac hypertrophy after
exercise
A. Analysis of representative heart sections of wild-type and CHIP −/− left ventricle in sham
and running groups stained with Mason's Trichrome (10× magnification; scale surrounding
each photomicrograph). B. Quantitative real-time PCR analysis for cardiac fetal genes
(βMHC, ANF, BNP) showing relative mRNA levels of indicated genes in heart from RUN
group compared to CON group were not significantly changed in both genotypes. At least 3
animals were used in each group. C. Fractional shortening (% FS) and ejection fraction (%
EF) calculated from data on echocardiography of mice from indicated groups (detailed data
shown in Table 2). Data represent means ± SEM.
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